Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals

Background: The COVID-19 pandemic highlighted the need for innovative vaccine platforms that elicit durable immunity. Self-amplifying RNA (saRNA) vaccines offer rapid production and dose-sparing advantages over traditional mRNA platforms. In Uganda’s first SARS-CoV-2 vaccine trial (NCT04934111), we...

Descrición completa

Detalles Bibliográficos

Principais autores:	Jonathan Kitonsa, Jennifer Serwanga, Hannah M. Cheeseman, Andrew Abaasa, Jane Frances Lunkuse, Eugene Ruzagira, Laban Kato, Florence Nambaziira, Gerald Kevin Oluka, Ben Gombe, Sembera Jackson, Joseph Katende Ssebwana, Leon R. McFarlane, Sarah Joseph, Benjamin F. Pierce, Robin J. Shattock, Pontiano Kaleebu
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2025-05-01
Series:	Vaccines
Assuntos:	self-amplifying RNA (saRNA) vaccine SARS-CoV-2 immunogenicity COVID-19 vaccination in Africa neutralising antibody responses spike-specific IgG antibodies vaccine safety and reactogenicity
Acceso en liña:	https://www.mdpi.com/2076-393X/13/6/553
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!